ArticleFrontiers in immunology2021
Subunit Vaccines Using TLR Triagonist Combination Adjuvants Provide Protection Against
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 41 citations in OpenAlex.
- What goes around comes around: updates in the study ofInfection and immunity · 2026Review
- The Squalene Oil-in-Water Nanoemulsion Vaccine Carrier AddaVax Potentiates TLR-Induced B-Cell Responses.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2026Article
- Control of human Q fever by vaccination: the journey to Q-VAX and beyond.Infection and immunity · 2025Review
- Innate Immune Response to Powassan Virus Infection: Progress Toward Infection Control.Vaccines · 2025Review
- Overview of the Q fever vaccine development: current status and future prospects.Antonie van Leeuwenhoek · 2025Review
- Molecular mechanisms ofInfection and immunity · 2024Article
- Vaccine development: obligate intracellular bacteria new tools, old pathogens: the current state of vaccines against obligate intracellular bacteria.Frontiers in cellular and infection microbiology · 2024Review
- Unveiling promising immunogenic targets in Coxiella burnetii through in silico analysis: paving the way for novel vaccine strategies.BMC infectious diseases · 2023Article
- Q fever immunology: the quest for a safe and effective vaccine.NPJ vaccines · 2023Review
- The Tick-Borne Pathogens: An Overview of China's Situation.Acta parasitologica · 2023Review
- Multivalent vaccines demonstrate immunogenicity and protect againstFrontiers in immunology · 2023Article
- Genome-wide epitope mapping across multiple host species reveals significant diversity in antibody responses toFrontiers in immunology · 2023Article
- An O-Specific Polysaccharide/Tetanus Toxoid Conjugate Vaccine Induces Protection in Guinea Pigs against Virulent Challenge withVaccines · 2022Article
- Preclinical Animal Models for Q Fever Vaccine Development.Frontiers in cellular and infection microbiology · 2022Review
- Immunogenicity and Reactogenicity in Q Fever Vaccine Development.Frontiers in immunology · 2022Review
- Soluble antigens derived fromCell reports. Medicine · 2021Article
- Recent Advances on the Innate Immune Response toFrontiers in cellular and infection microbiology · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
Abstract
Q fever is caused by the obligate intracellular bacterium,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.